Atlas Trials

Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Clinical trial NCT05410847 · UNKNOWN

Trial details

NCT number
NCT05410847
Sponsor
Hebei Medical University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Gastric Cancer
Start date
2022-06-30
Primary completion
2023-06-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.